Clinical trial · Interventional
Synchrotron Radiation to the Treatment of Intracranial Tumors
A Phase I-II Synchrotron Radiation Application to the Treatment of Intracranial Tumors
NCT01640509CI-TRIAL-00012620ESRFunknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to prove the safety and acceptability of treatment with the Synchrotron radiation by medium-term medical follow-up of the patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Cancer | Malignant Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| treated by synchrotron radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- synchrotron radiation
- description
- treated by synchrotron radiation
- interventionNames
- Radiation: treated by synchrotron radiation
Primary outcomes (1)
- measure
- Safety
- timeFrame
- 5 years
- description
- number of participant with adverse event (grade greater than 2), each adverse event will be gradueted according to Common Terminology Criteria for Adverse Events (CTCAE)Version 4.0
Secondary outcomes (4)
- measure
- Survival without limiting adverse events
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Controlled tumor disease in the primary site and no syndrome metastatic extracranial threatening short-term * Presence of 1 to 3 metastases brain symptomatic or not, metachronous primary cancer of a solid, proven itself by histopathological examination * In case of multiple lesions sites must be sufficiently spaced so that the PTV can be in separate horizontal planes * PS \< 2 Exclusion Criteria: * One or more lesions \> 3 cm in diameter on MRI, or infratentorial location * Performed surgical resection or formal indication * In progress or finished chemotherapy within the last 4 weeks * Partial or total irradiation of brain in the past , or total body irradiation * Presence of a second cancer that would be likely to render uncertain the identification of the origin of metastases
References
Publications (0)
Data not yet available
No reference posted for this study.